Efforts to improve education on biosimilars are a start, but payer policies must catch up to ensure real change.
Mike Gladstone
Advertisement
Articles by Mike Gladstone
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Capital Rx is now Judi Rx in a company rebrand
2
How the most favored nation drug pricing policy is quietly reshaping drug development and clinical research
3
Biomarker-guided PARP inhibition shows durable benefit in hormone-sensitive prostate cancer
4
Most patients with acute pain use opioids sparingly, study finds
5